BR112022024179A2 - Tratamento de câncer - Google Patents
Tratamento de câncerInfo
- Publication number
- BR112022024179A2 BR112022024179A2 BR112022024179A BR112022024179A BR112022024179A2 BR 112022024179 A2 BR112022024179 A2 BR 112022024179A2 BR 112022024179 A BR112022024179 A BR 112022024179A BR 112022024179 A BR112022024179 A BR 112022024179A BR 112022024179 A2 BR112022024179 A2 BR 112022024179A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- breast cancer
- cancer treatment
- treatment
- chemotherapy
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 abstract 1
- 102000017578 LAG3 Human genes 0.000 abstract 1
- 101150030213 Lag3 gene Proteins 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000012829 chemotherapy agent Substances 0.000 abstract 1
- 208000027706 hormone receptor-positive breast cancer Diseases 0.000 abstract 1
- 208000026534 luminal B breast carcinoma Diseases 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Marine Sciences & Fisheries (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008037.0A GB202008037D0 (en) | 2020-05-28 | 2020-05-28 | Treatment of cancer |
| RU2020131384A RU2020131384A (ru) | 2020-05-28 | 2020-09-23 | Лечение рака |
| GBGB2018062.6A GB202018062D0 (en) | 2020-11-17 | 2020-11-17 | Treatment of cancer |
| PCT/EP2021/057588 WO2021239292A1 (en) | 2020-05-28 | 2021-03-24 | Treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022024179A2 true BR112022024179A2 (pt) | 2023-02-07 |
Family
ID=75362569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022024179A BR112022024179A2 (pt) | 2020-05-28 | 2021-03-24 | Tratamento de câncer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230210946A1 (https=) |
| EP (1) | EP4157313A1 (https=) |
| JP (1) | JP2023527209A (https=) |
| KR (1) | KR20230028321A (https=) |
| CN (1) | CN116133674A (https=) |
| AU (1) | AU2021280214A1 (https=) |
| BR (1) | BR112022024179A2 (https=) |
| CA (1) | CA3184309A1 (https=) |
| IL (1) | IL298507A (https=) |
| MX (1) | MX2022014909A (https=) |
| WO (1) | WO2021239292A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4475955A1 (en) * | 2022-02-11 | 2024-12-18 | Immutep S.A.S. | Treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| GB201322626D0 (en) * | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
| GB201500374D0 (en) * | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
| JP2021534177A (ja) * | 2018-08-16 | 2021-12-09 | ジー１ セラピューティクス， インコーポレイテッド | 医学的障害を治療するためのベンゾチオフェンエストロゲン受容体モジュレーター |
| WO2020047329A1 (en) * | 2018-08-29 | 2020-03-05 | Shattuck Labs, Inc. | Chimeric proteins comprising extracellular domains and uses thereof |
-
2021
- 2021-03-24 IL IL298507A patent/IL298507A/en unknown
- 2021-03-24 BR BR112022024179A patent/BR112022024179A2/pt unknown
- 2021-03-24 MX MX2022014909A patent/MX2022014909A/es unknown
- 2021-03-24 CA CA3184309A patent/CA3184309A1/en active Pending
- 2021-03-24 WO PCT/EP2021/057588 patent/WO2021239292A1/en not_active Ceased
- 2021-03-24 JP JP2022573285A patent/JP2023527209A/ja active Pending
- 2021-03-24 US US17/928,048 patent/US20230210946A1/en active Pending
- 2021-03-24 KR KR1020227046217A patent/KR20230028321A/ko active Pending
- 2021-03-24 AU AU2021280214A patent/AU2021280214A1/en active Pending
- 2021-03-24 CN CN202180059063.2A patent/CN116133674A/zh active Pending
- 2021-03-24 EP EP21716087.8A patent/EP4157313A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230028321A (ko) | 2023-02-28 |
| JP2023527209A (ja) | 2023-06-27 |
| US20230210946A1 (en) | 2023-07-06 |
| IL298507A (en) | 2023-01-01 |
| AU2021280214A1 (en) | 2023-02-02 |
| EP4157313A1 (en) | 2023-04-05 |
| CA3184309A1 (en) | 2021-12-02 |
| CN116133674A (zh) | 2023-05-16 |
| MX2022014909A (es) | 2023-03-06 |
| WO2021239292A1 (en) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022012637A2 (pt) | Composto de piridazinil-tiazolcarboxamida, composição farmacêutica e inibidor da dgk ¿ que compreendem o mesmo e uso do dito composto para tratar câncer relacionado à ativação das células imunes ou câncer tendo resistência à terapia com anticorpo anti-pd-1 / anticorpo anti-pd-l1 | |
| Gschwantler-Kaulich et al. | Mesh versus acellular dermal matrix in immediate implant-based breast reconstruction–a prospective randomized trial | |
| CL2025002554A1 (es) | Compuestos tricíclicos inhibidores de parp1 y uso para tratar cáncer. | |
| CL2025003696A1 (es) | Compuestos macrocíclicos inhibidores de ras y su uso para tratar cáncer. | |
| Almeida et al. | Collagen implant with gentamicin sulphate reduces surgical site infection in vascular surgery: a prospective cohort study | |
| BR112018005777A2 (pt) | anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produzir um anticorpo de interesse ou um fragmento do mesmo composição farmacêutica, e, uso de pelo menos um anticorpo | |
| MX2020008977A (es) | Formulaciones de anticuerpos de her2 subcutaneas. | |
| MX2018015724A (es) | Metodos de tratamiento de cancer de mama que expresa el receptor de androgenos (ar+). | |
| CY1124616T1 (el) | Θεραπεια της μετα-βαριατρικης υπογλυκαιμιας με εξενδινη(9-39) | |
| MX389683B (es) | Composiciones terapeuticas, combinaciones y metodos de uso | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| BR112018008601A2 (pt) | composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer | |
| CO6290651A2 (es) | Inhibidores de cinesina como producto terapeuticos para el cancer | |
| MX2024000986A (es) | Compuestos y composiciones para el tratamiento de enfermedades relacionadas con el coronavirus. | |
| BR112023000654A2 (pt) | Composto de pirazolopirimidina usado como inibidor de atr quinase | |
| MX2021011230A (es) | Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades. | |
| BR112022024179A2 (pt) | Tratamento de câncer | |
| BR112022000251A2 (pt) | Derivados macrocíclicos de espirociclo como inibidores de mcl-1 | |
| Zoppellaro et al. | Primary thromboembolic prevention in multiple myeloma patients: an exploratory meta-analysis on aspirin use | |
| MX2024006934A (es) | Tratamiento del cancer con un inhibidor de la cinasa fgfr | |
| CO2024001405A2 (es) | Composiciones y métodos para el tratamiento de cáncer | |
| Bandalović et al. | A retrospective study of antibiotic prophylaxis value in surgical treatment of lower limb fracture | |
| CL2022002239A1 (es) | Tafoxiparina para el tratamiento de la preeclampsia | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| BR112022012081A2 (pt) | Método para tratar câncer, kit, e, uso de uma combinação terapêutica |